Therapeutic Vesicular Nanoreactors with Tumor-Specific Activation and Self-Destruction for Synergistic Tumor Ablation
Overview
Authors
Affiliations
Polymeric nanoreactors (NRs) have distinct advantages to improve chemical reaction efficiency, but the in vivo applications are limited by lack of tissue-specificity. Herein, novel glucose oxidase (GOD)-loaded therapeutic vesicular NRs (theraNR) are constructed based on a diblock copolymer containing poly(ethylene glycol) (PEG) and copolymerized phenylboronic ester or piperidine-functionalized methacrylate (P(PBEM-co-PEM)). Upon systemic injection, theraNR are inactive in normal tissues. At a tumor site, theraNR are specifically activated by the tumor acidity via improved permeability of the membranes. Hydrogen peroxide (H O ) production by the catalysis of GOD in theraNR increases tumor oxidative stress significantly. Meanwhile, high levels of H O induce self-destruction of theraNR releasing quinone methide (QM) to deplete glutathione and suppress the antioxidant ability of cancer cells. Finally, theraNR efficiently kill cancer cells and ablate tumors via the synergistic effect.
Supramolecular Nanozymes Based on Self-Assembly of Biomolecule for Cancer Therapy.
Hu P, Zheng J, Wang H, Li Y, Ye T, Li Q Int J Nanomedicine. 2025; 20:2043-2057.
PMID: 39990286 PMC: 11842878. DOI: 10.2147/IJN.S496831.
Harnessing glucose metabolism with nanomedicine for cancer treatment.
Wang X, Wang L, Hao Q, Cai M, Wang X, An W Theranostics. 2024; 14(17):6831-6882.
PMID: 39479443 PMC: 11519798. DOI: 10.7150/thno.100036.
Current status and prospects of MOFs loaded with HO-related substances for ferroptosis therapy.
Deng Y, Huang S, Jiang G, Zhou L, Nezamzadeh-Ejhieh A, Liu J RSC Med Chem. 2024; 15(9):2996-3016.
PMID: 39309362 PMC: 11411616. DOI: 10.1039/d4md00261j.
Biochemical hallmarks-targeting antineoplastic nanotherapeutics.
Han J, Dong H, Zhu T, Wei Q, Wang Y, Wang Y Bioact Mater. 2024; 36:427-454.
PMID: 39044728 PMC: 11263727. DOI: 10.1016/j.bioactmat.2024.05.042.
Recent advances in glucose oxidase-based nanocarriers for tumor targeting therapy.
Li S, Wang Q, Jia Z, Da M, Zhao J, Yang R Heliyon. 2023; 9(10):e20407.
PMID: 37780773 PMC: 10539972. DOI: 10.1016/j.heliyon.2023.e20407.